An Unexpected Association: Might GAVE Pave the Way to How the Metabolic Syndrome Behaves
Ravi Jariwala, Mohamed Shoreibah – 6 December 2021
Travel for Transplantation: A Review of Domestic and International Travel for Liver Transplantation in the United States
Hillary J. Braun, Nancy L. Ascher – 6 December 2021
Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron‐induced hepatotoxicity
Hui Xiong, Chunze Zhang, Lifeng Han, Tong Xu, Khawar Saeed, Jing Han, Jing Liu, Curtis D. Klaassen, Frank J. Gonzalez, Yuanfu Lu, Youcai Zhang – 5 December 2021
Introducing Laurie DeLeve, M.D., Ph.D., Our 2022 AASLD President
Neil Kaplowitz – 5 December 2021
Introducing Laurie DeLeve, M.D., Ph.D., Our 2022 AASLD President
Neil Kaplowitz – 5 December 2021
Superior Long‐Term Outcomes of Adult Living Donor Liver Transplantation: A Cumulative Single‐Center Cohort Study With 20 Years of Follow‐Up
Toru Goto, Tommy Ivanics, Mark S. Cattral, Trevor Reichman, Anand Ghanekar, Gonzalo Sapisochin, Ian D. McGilvray, Blayne Sayed, Les Lilly, Mamatha Bhat, Markus Selzner, Nazia Selzner – 5 December 2021 – Living donor liver transplantation (LDLT) is an attractive alternative to deceased donor liver transplantation (DDLT). Although both modalities have similar short‐term outcomes, long‐term outcomes are not well studied. We compared the 20‐year outcomes of 668 adults who received LDLT with1596 DDLTs at the largest liver transplantation (LT) program in Canada.
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study
Jennifer C. Lai, Amy M. Shui, Andres Duarte‐Rojo, Daniel R. Ganger, Robert S. Rahimi, Chiung‐Yu Huang, Frederick Yao, Matthew Kappus, Brian Boyarsky, Mara McAdams‐Demarco, Michael L. Volk, Michael A. Dunn, Daniela P. Ladner, Dorry L. Segev, Elizabeth C. Verna, Sandy Feng, from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study – 3 December 2021
Letter to the editor: Exacerbation of autoimmune hepatitis after COVID‐19 vaccination
Zhujun Cao, Honglian Gui, Zike Sheng, Haiguang Xin, Qing Xie – 3 December 2021
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, Fatih Karakaya, Çağdaş Kalkan, Ersin Karatayli, Senem Karatayli, Ingrid Choong, David Apelian, Christopher Koh, Theo Heller, Ramazan Idilman, A. Mithat Bozdayi, Jeffrey S. Glenn – 2 December 2021
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
Gonzalo Sapisochin, Tommy Ivanics, Julie Heimbach – 2 December 2021 – Cholangiocarcinoma (CCA) represents the second‐most common primary liver malignancy after HCC and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested that iCCA may be a potentially feasible option for highly selected patients.